Replies to post #214319 on Biotech Values

[DewDiligence]

ENTA—Mavyret scripts for week ending 10/13/17 (according to IMS)….

TRx: 618, +17.5% vs prior week
NRx: 358, +2.0% vs prior week

We are now eleven weeks into the US launch.

(As previously noted, Mavyret’s absolute script numbers reported by IMS are low because IMS misses much of the public sector of the HCV market that ABBV is targeting.)